Mayo Clinic Laboratory and Pathology Research Roundup: Sept. 10

By Kelley Luedke • September 10, 2018

Share this:

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.

Featured Abstract

Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation

Early detection improves hepatocellular carcinoma (HCC) outcomes, but better noninvasive surveillance tools are needed. Mayo Clinic researchers aimed to identify and validate methylated DNA markers (MDMs) for HCC detection. Reduced representation bisulfite sequencing was performed on DNA extracted from 18 HCC and 35 control tissues. A phase I plasma pilot incorporated quantitative allele-specific real time target and signal amplification assays on independent plasma-extracted DNA from 21 HCC cases and 30 cirrhotic controls. A phase II plasma study was then performed in 95 HCC cases, 51 cirrhosis controls, and 98 healthy controls using target enrichment long-probe quantitative amplified signal (TELQAS) assays. Based on the results, novel MDMs identified in this study proved to accurately detect HCC via plasma testing. Further optimization and clinical testing of this promising approach are indicated. The study was published in Case Reports in Hepatology.

Published to PubMed This Week

• • • • • Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway
          Cell Metabolism
        • Use of High-Sensitivity Cardiac Troponin in Patients With Chronic Comorbidities: Moving From Theory to Practice
          Journal of the American College of Cardiology
        • A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology
          Clinical Infectious Diseases
        • Ganglionic Antibody Level as a Predictor of Severity of Autonomic Failure
          Mayo Clinic Proceedings
        • Recurrent Desmoid-Type Fibromatosis Associated with Underlying Neuromuscular Choristoma
          Journal of Neurosurgery
        • A Pediatric Intra-Axial Malignant SMARCB1-Deficient Desmoplastic Tumor Arising in Meningioangiomatosis
          Journal of Neuropathology & Experimental Neurology
        • DNA Methylation at the Vicinity of the Proximal Polyadenylation Site in FANCD2 Gene Involves Human Malignancy
          Cell Cycle
        • Heterogeneity of Programmed Cell Death-Ligand 1 Expression in Thymic Epithelial Tumors Between Initial Specimen and Synchronous or Metachronous Metastases or Recurrences
          Histopathology
        • A Method to Reduce Variability in Scoring Anti-Body Mediated Rejection in Renal Allografts: Implications for Clinical Trials
          Transplant International
          
        • Corded and Hyalinized Mesonephric-Like Adenocarcinoma of the Uterine Corpus: Report of a Case Mimicking Endometrioid Carcinoma
          Human Pathology
          
        • Reference Intervals: Comparison of Calculation Methods and Evaluation of Procedures for Merging Reference Measurements From Two US Medical Centers
          American Journal of Clinical Pathology
          
        • A Cavernous Sinus Lesion Clinically Responsive to Steroids
          Journal of Clinical Neuroscience

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.